Repeated red light therapy can slow myopia progression in premyopic children, but discontinuation may cause a rebound effect in axial growth.

An exclusive program uniting the top 12% of U.S. MiSight day prescribers to advance myopia management strategies.

Abstract: Robotic autonomous grasp requires the system to perform multiple functions such as gripper and robot control, making it a task with hybrid output nature. Existing methods based on ...

The US launch of a myopia control spectacle lens, research into modifiable myopia risk factors, and atropine developments ...

Essilorluxottica (OTC) ((ESLOY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SYD-101 met its primary phase 3 efficacy endpoint, but ...

Submitted data were not enough to support the effectiveness of SYD-101 in children with myopia, according to the FDA. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) ...

The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving primary efficacy in the STAR trial. The STAR trial demonstrated significant ...